NCT03603951View on ClinicalTrials.gov

A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

272

Participants

Timeline

Start Date

August 14, 2018

Primary Completion Date

February 14, 2026

Study Completion Date

August 14, 2026

Conditions
Relapsed or Refractory Mature Lymphoid Neoplasms
Interventions
DRUG

SHR2554

SHR2554 is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2.

Trial Locations (1)

Unknown

Beijing Cancer Hospital, Peking University, Beijing

All Listed Sponsors
collaborator

Peking University Cancer Hospital & Institute

OTHER

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY